The first report of the presence of alternative lengthening of telomeres (ALT) in cancers arising from the bladder, cervix, endometrium, esophagus, gallbladder, liver, and lung was published today in The American Journal ...
Sep 1, 2011
0
0
Researchers have created a new phenotypic screening platform that better predicts success of drugs developed to prevent blood vessel tumor growth when moving out of the lab and onto actual tumors.
Nov 13, 2011
0
0
Testing patients with non-small cell lung cancer for both mutations and amplifications of the KRAS gene prior to therapy may help to predict response to treatment with antifolates, according to the updated results of a preclinical ...
Apr 4, 2012
0
0
Cancer Research UK scientists have taken steps to overcome drug resistance in glioblastoma, the most common type of brain tumour in adults, according to research published in Molecular Cancer Therapeutics.
Jan 14, 2015
0
11
MIT biologists have identified a new biomarker that can reveal whether patients with a particularly aggressive type of breast cancer will be helped by paclitaxel (commercially known as Taxol), one of the drugs most commonly ...
Nov 22, 2016
0
83
Glioblastoma multiforme (GBM) is one of the most aggressive, fast-growing tumor types, and the most common cancer of the brain with a median overall survival of approximately 15 months. Despite recent advances in treatment ...
Aug 2, 2022
0
5
In a study recently published in Cancer Research, Van Andel Research Institute (VARI) researchers found a protein that could help predict the spread of the head and neck cancer nasopharyngeal carcinoma (NPC); this protein ...
Jun 14, 2011
0
0
A novel agent that targets a mutated form of the KRAS gene—the most commonly altered oncogene in human cancers and one long considered "undruggable"—shrank tumors in most patients in a clinical trial with manageable side ...
Oct 25, 2020
0
17
More than 20 years after scientists revealed that mutations in the BRCA1 gene predispose women to breast cancer, Yale scientists have pinpointed the molecular mechanism that allows those mutations to wreak their havoc.
Oct 4, 2017
0
26
Researchers report that a drug targeting the cancer-causing gene MYC inhibits the function of the gene in a phase I clinical trial. Until now, no other drug has been able to do this safely and effectively.
Oct 26, 2022
0
10
